Published in Mol Cancer Ther on December 27, 2011
PDGFR blockade is a rational and effective therapy for NPM-ALK-driven lymphomas. Nat Med (2012) 1.67
ALK inhibitors in non-small cell lung cancer: crizotinib and beyond. Clin Adv Hematol Oncol (2014) 1.48
New molecular insights into peripheral T cell lymphomas. J Clin Invest (2012) 1.02
A novel patient-derived tumorgraft model with TRAF1-ALK anaplastic large-cell lymphoma translocation. Leukemia (2014) 0.93
Targeting autophagy enhances the anti-tumoral action of crizotinib in ALK-positive anaplastic large cell lymphoma. Oncotarget (2015) 0.91
Mechanisms of Acquired Resistance to ALK Inhibitors and the Rationale for Treating ALK-positive Lung Cancer. Cancers (Basel) (2015) 0.90
The EGFR family members sustain the neoplastic phenotype of ALK+ lung adenocarcinoma via EGR1. Oncogenesis (2013) 0.89
ALK Signaling and Target Therapy in Anaplastic Large Cell Lymphoma. Front Oncol (2012) 0.88
Anaplastic lymphoma kinase is required for neurogenesis in the developing central nervous system of zebrafish. PLoS One (2013) 0.87
The R1275Q neuroblastoma mutant and certain ATP-competitive inhibitors stabilize alternative activation loop conformations of anaplastic lymphoma kinase. J Biol Chem (2012) 0.87
ALK inhibitors in non-small cell lung cancer: the latest evidence and developments. Ther Adv Med Oncol (2016) 0.86
STAT3-mediated activation of microRNA cluster 17~92 promotes proliferation and survival of ALK-positive anaplastic large cell lymphoma. Haematologica (2013) 0.86
Treating patients with ALK-positive non-small cell lung cancer: latest evidence and management strategy. Ther Adv Med Oncol (2015) 0.76
Oncogenic kinase fusions: an evolving arena with innovative clinical opportunities. Oncotarget (2016) 0.76
Therapeutic efficacy of the bromodomain inhibitor OTX015/MK-8628 in ALK-positive anaplastic large cell lymphoma: an alternative modality to overcome resistant phenotypes. Oncotarget (2016) 0.76
Smac mimetic LCL161 supports neuroblastoma chemotherapy in a drug class-dependent manner and synergistically interacts with ALK inhibitor TAE684 in cells with ALK mutation F1174L. Oncotarget (2016) 0.76
Anaplastic lymphoma kinase (ALK) inhibitors for second-line therapy of non-small cell lung cancer. Lung Cancer (Auckl) (2012) 0.75
Anaplastic lymphoma kinase-positive large B-cell lymphoma: Clinico-pathological study of 17 cases with review of literature. PLoS One (2017) 0.75
BRAF mutations in hairy-cell leukemia. N Engl J Med (2011) 7.05
Stat3 is required for ALK-mediated lymphomagenesis and provides a possible therapeutic target. Nat Med (2005) 6.45
The anaplastic lymphoma kinase in the pathogenesis of cancer. Nat Rev Cancer (2008) 5.07
Beta 4 integrin amplifies ErbB2 signaling to promote mammary tumorigenesis. Cell (2006) 4.48
Oncogenic kinase NPM/ALK induces through STAT3 expression of immunosuppressive protein CD274 (PD-L1, B7-H1). Proc Natl Acad Sci U S A (2008) 2.99
Anaplastic lymphoma kinase (ALK) activates Stat3 and protects hematopoietic cells from cell death. Oncogene (2002) 2.36
Ablation of oncogenic ALK is a viable therapeutic approach for anaplastic large-cell lymphomas. Blood (2005) 2.15
A targeted mutational landscape of angioimmunoblastic T-cell lymphoma. Blood (2013) 2.14
Anaplastic lymphoma kinase in human cancer. J Mol Endocrinol (2011) 1.95
PAX genes: roles in development, pathophysiology, and cancer. Biochem Pharmacol (2006) 1.93
Mechanism-based epigenetic chemosensitization therapy of diffuse large B-cell lymphoma. Cancer Discov (2013) 1.90
The coding genome of splenic marginal zone lymphoma: activation of NOTCH2 and other pathways regulating marginal zone development. J Exp Med (2012) 1.90
NPM-ALK transgenic mice spontaneously develop T-cell lymphomas and plasma cell tumors. Blood (2002) 1.87
Pre-steady-state and steady-state kinetic analysis of E. coli class I ribonucleotide reductase. Biochemistry (2003) 1.68
PDGFR blockade is a rational and effective therapy for NPM-ALK-driven lymphomas. Nat Med (2012) 1.67
Chemopotentiation of temozolomide, irinotecan, and cisplatin activity by CEP-6800, a poly(ADP-ribose) polymerase inhibitor. Mol Cancer Ther (2003) 1.59
CEP-18770: A novel, orally active proteasome inhibitor with a tumor-selective pharmacologic profile competitive with bortezomib. Blood (2007) 1.54
Functional validation of the anaplastic lymphoma kinase signature identifies CEBPB and BCL2A1 as critical target genes. J Clin Invest (2006) 1.51
Anaplastic lymphoma kinase activity is essential for the proliferation and survival of anaplastic large-cell lymphoma cells. Blood (2005) 1.49
STAT3: a multifaceted oncogene. Proc Natl Acad Sci U S A (2006) 1.48
Follicular origin of a subset of CD5+ diffuse large B-cell lymphomas. Am J Clin Pathol (2005) 1.43
Simple genetic diagnosis of hairy cell leukemia by sensitive detection of the BRAF-V600E mutation. Blood (2011) 1.42
Gene expression profiling uncovers molecular classifiers for the recognition of anaplastic large-cell lymphoma within peripheral T-cell neoplasms. J Clin Oncol (2010) 1.31
Knowledge-Based, Central Nervous System (CNS) Lead Selection and Lead Optimization for CNS Drug Discovery. ACS Chem Neurosci (2011) 1.30
Multigram synthesis of the C29-C51 subunit and completion of the total synthesis of altohyrtin C (spongistatin 2). J Am Chem Soc (2003) 1.27
Molecular profiling improves classification and prognostication of nodal peripheral T-cell lymphomas: results of a phase III diagnostic accuracy study. J Clin Oncol (2013) 1.22
Discovery of a potent, selective, and orally active proteasome inhibitor for the treatment of cancer. J Med Chem (2008) 1.22
The PD-1/PD-L1 axis contributes to T-cell dysfunction in chronic lymphocytic leukemia. Haematologica (2013) 1.21
The anaplastic lymphoma kinase is an effective oncoantigen for lymphoma vaccination. Nat Med (2008) 1.19
S-phase kinase-associated protein 2 expression in non-Hodgkin's lymphoma inversely correlates with p27 expression and defines cells in S phase. Am J Pathol (2002) 1.17
p130Cas mediates the transforming properties of the anaplastic lymphoma kinase. Blood (2005) 1.16
1,2,3-Thiadiazole substituted pyrazolones as potent KDR/VEGFR-2 kinase inhibitors. Bioorg Med Chem Lett (2006) 1.14
In vivo interference with Skp1 function leads to genetic instability and neoplastic transformation. Mol Cell Biol (2002) 1.13
ALK/EML4 fusion gene may be found in pure squamous carcinoma of the lung. J Thorac Oncol (2014) 1.11
Epidermal growth factor receptor gene in primary tumor and metastatic sites from non-small cell lung cancer. J Thorac Oncol (2009) 1.10
CD73-generated extracellular adenosine in chronic lymphocytic leukemia creates local conditions counteracting drug-induced cell death. Blood (2011) 1.09
The tyrosine phosphatase Shp2 interacts with NPM-ALK and regulates anaplastic lymphoma cell growth and migration. Cancer Res (2007) 1.08
NPM-ALK oncogenic tyrosine kinase controls T-cell identity by transcriptional regulation and epigenetic silencing in lymphoma cells. Cancer Res (2009) 1.07
Mixed lineage kinase activity of indolocarbazole analogues. Bioorg Med Chem Lett (2002) 1.06
Two main genetic pathways lead to the transformation of chronic lymphocytic leukemia to Richter syndrome. Blood (2013) 1.06
Constant activation of the RAF-MEK-ERK pathway as a diagnostic and therapeutic target in hairy cell leukemia. Haematologica (2013) 1.06
A highly selective, orally active inhibitor of Janus kinase 2, CEP-33779, ablates disease in two mouse models of rheumatoid arthritis. Arthritis Res Ther (2011) 1.05
Amplification of Her-2/neu gene in Her-2/neu-overexpressing and -nonexpressing breast carcinomas and their synchronous benign, premalignant, and metastatic lesions detected by FISH in archival material. Mod Pathol (2002) 1.05
MicroRNA expression profiling identifies molecular signatures associated with anaplastic large cell lymphoma. Blood (2013) 1.02
Depletion of autoreactive plasma cells and treatment of lupus nephritis in mice using CEP-33779, a novel, orally active, selective inhibitor of JAK2. J Immunol (2011) 1.02
Constitutive expression of DeltaN-p63alpha isoform in human thymus and thymic epithelial tumours. Virchows Arch (2003) 1.01
Identification of a 3-gene model as a powerful diagnostic tool for the recognition of ALK-negative anaplastic large-cell lymphoma. Blood (2012) 1.01
The neurotrophin-trk receptor axes are critical for the growth and progression of human prostatic carcinoma and pancreatic ductal adenocarcinoma xenografts in nude mice. Clin Cancer Res (2002) 0.99
Anaplastic large cell lymphoma: one or more entities among T-cell lymphoma? Hematol Oncol (2009) 0.98
Tim-3+ T-bet+ tumor-specific Th1 cells colocalize with and inhibit development and growth of murine neoplasms. J Immunol (2005) 0.98
Effects of the isoprenoids perillyl alcohol and farnesol on apoptosis biomarkers in pancreatic cancer chemoprevention. Anticancer Res (2003) 0.98
Genome wide DNA-profiling of HIV-related B-cell lymphomas. Br J Haematol (2009) 0.97
The anaplastic lymphoma kinase controls cell shape and growth of anaplastic large cell lymphoma through Cdc42 activation. Cancer Res (2008) 0.97
Anomalous surface distribution of glycosyl phosphatidyl inositol-anchored proteins in neurons lacking acid sphingomyelinase. Mol Biol Cell (2007) 0.96
Metabolism-directed optimization of 3-aminopyrazinone acetamide thrombin inhibitors. Development of an orally bioavailable series containing P1 and P3 pyridines. J Med Chem (2003) 0.95
Potent, selective, orally bioavailable inhibitors of tumor necrosis factor-alpha converting enzyme (TACE): discovery of indole, benzofuran, imidazopyridine and pyrazolopyridine P1' substituents. Bioorg Med Chem Lett (2008) 0.95
Genomic profiling of Richter's syndrome: recurrent lesions and differences with de novo diffuse large B-cell lymphomas. Hematol Oncol (2010) 0.95
PRDM1/BLIMP1 is commonly inactivated in anaplastic large T-cell lymphoma. Blood (2013) 0.94
Pathobiology of anaplastic large cell lymphoma. Adv Hematol (2011) 0.93
Novel, orally active, proteasome inhibitor, delanzomib (CEP-18770), ameliorates disease symptoms and glomerulonephritis in two preclinical mouse models of SLE. Int Immunopharmacol (2011) 0.90
PAX6 is expressed in pancreatic adenocarcinoma and is downregulated during induction of terminal differentiation. Mol Carcinog (2008) 0.90
Diffuse large B-cell lymphoma with concordant bone marrow involvement has peculiar genomic profile and poor clinical outcome. Hematol Oncol (2011) 0.89
Deregulation of ETS1 and FLI1 contributes to the pathogenesis of diffuse large B-cell lymphoma. Blood (2013) 0.88
ALK Signaling and Target Therapy in Anaplastic Large Cell Lymphoma. Front Oncol (2012) 0.88
Phosphoregulation of mixed-lineage kinase 1 activity by multiple phosphorylation in the activation loop. Biochemistry (2004) 0.88
Core binding factor acute myeloid leukaemia and c-KIT mutations. Oncol Rep (2013) 0.88
Synthesis and structure-activity relationships of 4,5-fused pyridazinones as histamine H₃ receptor antagonists. Bioorg Med Chem Lett (2011) 0.88
Genomic lesions associated with a different clinical outcome in diffuse large B-Cell lymphoma treated with R-CHOP-21. Br J Haematol (2010) 0.87
p27Kip1 repression of ErbB2-induced mammary tumor growth in transgenic mice involves Skp2 and Wnt/beta-catenin signaling. Cancer Res (2006) 0.87
The Public Repository of Xenografts Enables Discovery and Randomized Phase II-like Trials in Mice. Cancer Cell (2016) 0.87
STAT3-mediated activation of microRNA cluster 17~92 promotes proliferation and survival of ALK-positive anaplastic large cell lymphoma. Haematologica (2013) 0.86
T-cell clonality and myelodysplasia without chromosomal fragility in a patient with features of Seckel syndrome. Haematologica (2003) 0.85
ALK mutants in the kinase domain exhibit altered kinase activity and differential sensitivity to small molecule ALK inhibitors. Biochemistry (2009) 0.85